Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBT: 2018-2024

Historic EBT for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to -$80.9 million.

  • Arcturus Therapeutics Holdings' EBT fell 88.88% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 6.94%. This contributed to the annual value of -$80.9 million for FY2024, which is 190.23% down from last year.
  • As of FY2024, Arcturus Therapeutics Holdings' EBT stood at -$80.9 million, which was down 190.23% from -$27.9 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' EBT's 5-year high stood at $10.6 million during FY2022, with a 5-year trough of -$203.7 million in FY2021.
  • Moreover, its 3-year median value for EBT was -$27.9 million (2023), whereas its average is -$32.7 million.
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' EBT skyrocketed by 105.23% in 2022 and then tumbled by 362.03% in 2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' EBT (Yearly) stood at -$71.5 million in 2020, then tumbled by 184.76% to -$203.7 million in 2021, then surged by 105.23% to $10.6 million in 2022, then slumped by 362.03% to -$27.9 million in 2023, then plummeted by 190.23% to -$80.9 million in 2024.